Our policy on cancer drugs
We believe that all cancer patients in the UK should be able to access the best, evidence-based drugs available for their condition.
The Government must balance the need to spend the health budget carefully with the need to guarantee access to effective drugs. It must also create the right incentives for industry to produce innovative new medicines.
Regulators must ensure that only drugs that are safe and that work will reach patients as quickly as possible.
It is a time of great change in this area, with the introduction of new arrangements for commissioning and paying for chemotherapy in England in 2013. In different parts of the UK, policy makers and bodies such as the NICE and the Scottish Medicines Consortium are developing new approached to providing access to medicines.
We work to ensure that government policy helps cancer patients to access the drugs they need.
Cancer patients’ views on government plans to introduce value-based pricing for medicines
Response to NHS England and NICE consultation on Cancer Drugs Fund reform
Response to the NHS England consultation on revisions to the Standard Operating Procedures for the Cancer Drugs Fund
Response to NICE review of the methods for Technology Appraisal
Response to NICE review of the guide to the processes of Technology Appraisal
Consultation on revisions to the statutory scheme for medicines pricing
Cancer Drugs Fund: a consultation
Commissioned research brief
Access to chemopreventative drugs (January 2016)
Initial expressions of interest by 28th January 2016
Get in touch with our policy team to find out more information about our policy on access to cancer treatments.
Call our policy team for more information.